| Patient | Emily Dickinson |
|---|---|
| Date of birth | 1971-12-10 |
| Identifiers | MRN HR-NI023-SYN; SSN (made up) 000-23-6081 |
| Document date | 2026-01-12 |
| Author | Lucinda Hartwell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
1 later historical claim is omitted because it describes events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| Late winter of 1848 | Lung congestion and cough; removed from her seminary for about a month | D (CLM-0002) |
| 1851 | Symptoms then thought to be consumptive, treated with a glycerine prescription for about two years until they subsided; no tuberculosis diagnosis is documented | D (CLM-0003) |
| 1863 to 1865 | Eye affliction with sensitivity to light and aching eyes, treated by a Boston ophthalmologist with dim light and no reading during two long stays in Cambridgeport; apparently cured. The diagnosis is not recorded (iritis most often proposed) | R (CLM-0004, CLM-0005, CLM-0006) |
| October 1883 | Nervous prostration after a death in her family, followed by continuing ill health | D (CLM-0010) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 2025-10-01 to 2026-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 to 2026-02-02 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-01-12 | active | S |
Positive for the concerns in the history of present illness. Alert, precise, and articulate; quiet voice; answers fully but briefly and prefers to add details in writing. Mood "tired, not sad"; affect reactive with dry humor; no suicidal ideation; cognition intact. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. At intake, independent in all activities of daily living; headaches and tiredness cut her writing mornings short on most days. Writing full mornings again and free of regular headaches by the six-month review. [S]
Vital signs recorded on 2026-01-12; see the Vital Signs section. Mental status: Alert, precise, and articulate; quiet voice; answers fully but briefly and prefers to add details in writing; Mood "tired, not sad"; affect reactive with dry humor; no suicidal ideation; cognition intact. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-12 | Body height | 163 | cm | S |
| 2026-01-12 | Body weight | 54 | kg | S |
| 2026-01-12 | Body mass index (BMI) [Ratio] | 20.3 | kg/m2 | S |
| 2026-01-12 | Systolic blood pressure | 166 | mm[Hg] | S |
| 2026-01-12 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 2026-01-12 | Heart rate | 78 | /min | S |
| 2026-01-12 | Respiratory rate | 14 | /min | S |
| 2026-01-12 | Body temperature | 36.6 | Cel | S |
| 2026-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-12 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-12 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-01-12 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 6-21 mg/dL | Normal | S |
| 2026-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 54 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-01-12 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-12 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-01-12 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-01-12 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 74 | pg/mL | 15-65 pg/mL | High | S |
| 2026-01-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 21 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-01-12 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-01-12 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-01-12 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-01-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-01-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 134 | mg/dL | <=99 mg/dL | High | S |
| 2026-01-12 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-01-12 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-01-12 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | <=30 mg/g | High | S |
| 2026-01-12 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 1 | /[HPF] | <=2 /[HPF] | Normal | S |
| 2026-01-12 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.5 | % | S | ||
| 2026-01-12 | Kidney failure 5-year risk [Likelihood] by KFRE | 1.6 | % | S | ||
| 2026-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-01-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | E55.9 | S — Synthetic laboratory finding at the intake visit. |